相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913
Sabina Chiaretti et al.
HAEMATOLOGICA (2021)
Management of ETV6-ABL1-positive childhood acute lymphoblastic leukaemia: report of two cases, a literature review and a call for action
Jiajia Zheng et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan
Yin-Chen Hsu et al.
SCIENTIFIC REPORTS (2021)
Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias
Andrea Biloglav et al.
GENES CHROMOSOMES & CANCER (2020)
Multidisciplinary analysis of pediatric T-ALL: 9q34 gene fusions
Peter Papenhausen et al.
CANCER GENETICS (2019)
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use
Ashwini K. Yenamandra et al.
LABORATORY MEDICINE (2019)
Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1
Ibrahim Aldoss et al.
LEUKEMIA & LYMPHOMA (2019)
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
Ilaria Tanasi et al.
BLOOD (2019)
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications
Sabina Chiaretti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours
Xiaotu Ma et al.
NATURE (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia
Thai Hoa Tran et al.
BLOOD ADVANCES (2018)
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
Shalini C. Reshmi et al.
BLOOD (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemia
Toby Eyre et al.
BLOOD (2012)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia
Thomas Ernst et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL)
P. M. Kakadia et al.
LEUKEMIA (2011)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
分享论文
